Humana (NYSE:HUM) Price Target & New Coverage by Goldman Sachs
In an analyst note sent to investors on 3 January, equity research analysts at Goldman Sachs began coverage on shares of Humana (NYSE:HUM). The firm set a “Buy” rating with $305.0, giving 19.44 % to target.
According to data compiled by Thomson Reuters, Humana (NYSE:HUM)’s stock is covered by 15 equity analysts across the Street, with 0 analysts giving it a Sell rating, 6 a Buy rating, while 13 consider it a Hold. The 12-month consensus target price for the stock is $205.93, which reflects an downside potential of 15.11% over the current price.
Glenview Capital Management Llc had the largest stake with ownership of 9.53M shares as of Q2 2015 for 12.06% of the US equity exposure. Jet Capital Investors L P is another very bullish fund who is owning 719,209 shares of Humana or 8.97% of their US equity exposure. Furthermore, Fort L.P. have 7.25% of their US equity exposure invested in the company for 118,950 shares. The New York-based fund Clovis Capital Management Lp disclosed it had acquired so far a stake worth about 4.8% of the fund’s stock portfolio in Humana. The New York-based fund Arrowgrass Capital Partners (Us) Lp is also positive about the stock, possessing 86,460 shares or 4.66% of their US equity exposure.
Humana (NYSE:HUM) Profile
Humana Inc. is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Humana (NYSE:HUM) traded down -0.40% on 3 January, hitting $242.59. A total of 1.74 million shares of the company’s stock traded hands. This is up from average of 1.22 million shares. Humana has a 52 week low of $186.25 and a 52 week high of $264.56. The company has a market cap of $34.80 billion and a P/E ratio of 19.17.
Get the latest Humana (NYSE:HUM) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Humana (NYSE:HUM) Coverage Started by Goldman Sachs. The Firm’s Target Price per Share is $305.0 appeared first on Octafinance.